Medrad prostate ecoil

Clinical imaging was acquired using a single 3T scanner (Discovery MR750, General Electric, Waukesha, WI) with an endorectal coil (Medrad Prostate eCoil, Bayer Healthcare, Warrendale, PA). The MP protocol included T2 weighted imaging, dynamic contrast-enhanced imaging, and field of view optimized and constrained single-shot diffusion with 10 $b$ -values (0, 10, 25, 50, 80, 100, 200, 500, 1000, and $2000{\mathrm{s}/\mathrm{mm}}^2$ ). The imaging was processed as previously published.¹⁸ (link)^,19 (link) The images used to generate the radiopathomic maps were intensity normalized T2, ADC ( $b=0$ and $1000{\mathrm{s}/\mathrm{mm}}^2$ ), ADC ( $b=1000$ and $2000{\mathrm{s}/\mathrm{mm}}^2$ ), ADC ( $b=500$ and $2000{\mathrm{s}/\mathrm{mm}}^2$ ), $b=0$ , and a T1 subtraction map.¹⁸ (link)^–20 (link, link)

Images were acquired on a 3-Tesla magnet (Discovery^TM MR750 or Discovery^TM MR750w GEM (GE Healthcare LLC, Arlington Heights, IL) using an endorectal coil (MEDRAD^® Prostate eCoil, Bayer HealthCare LLC. Whippany, NJ). The protocol followed the PI-RADS v2 guidelines and included high-resolution T2-weighted images, high b-value diffusion-weighted images, and dynamic contrast-enhanced images (1 (link)). Details are provided in Appendix 1.